Advertisement

Journal of Hematopathology

, Volume 12, Issue 3, pp 163–168 | Cite as

Co-occurrence of CALR and MPL somatic mutations in an Indian patient with a Philadelphia-negative myeloproliferative neoplasm

  • Ketki KelkarEmail author
  • Vijay Ramanan
  • Siddharth Anand
  • Shatakshi Ranade
  • Kunal Patil
  • Meenal Agarwal
  • Nikhil Phadke
Case Report
  • 33 Downloads

Abstract

Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of clonal disorders that are characterized by excessive proliferation of abnormal myeloid precursors and mature cells. Somatic driver mutations in the JAK2, CALR, and MPL genes serve as major diagnostic criteria in the classification of the MPNs, namely polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Although initially thought to be mutually exclusive, recent studies have reported the co-existence of JAK2, MPL, and CALR mutations. In this case report, we describe a case of a Philadelphia-negative myeloproliferative neoplasm harboring mutations in the CALR [NM_004343.3:c.1092_1143del52 (NP_004334.1:p.Leu367Thrfs)] and MPL [NM_005373.2:c.1543T>A (NP_005364.1:p.Try515Arg)] genes. Given the rarity of documented co-occurrence of driver mutations in these two genes and the concomitant paucity of data regarding management of patients harboring mutations in both these genes simultaneously, there are no clear guidelines for the treatment of patients with these mutation patterns and hence it is difficult to assess the true relevance of this genotype. The fact that both the MPL and CALR genes are a part of the JAK-STAT pathway could, however, assist in the clinical decision-making process.

Keywords

CALR Doubly mutated Essential thrombocythemia MPL Myeloproliferative neoplasm Next-generation sequencing 

Notes

Acknowledgments

We would like to thank the team from GenePath Diagnostics: Asawari Pilankar, Ashwini Bapat, Karthik Ganesan, Kavita Khatod, Neher Parimoo, Priyanka Gangodkar, Purvi Majethia, Trupti Ragte-Wathare, and Vidula Sengaonkar.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Frawley T, O’Brien C, Conneally E et al (2018) Development of a targeted next-generation sequencing assay to detect diagnostically relevant mutations of JAK2, CALR, and MPL in myeloproliferative neoplasms. Genet Test Mol Biomarkers 22:98–103CrossRefPubMedGoogle Scholar
  2. 2.
    McGaffin G, harper K, Stirling D et al (2014) JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br J Hematol 167:276–278CrossRefGoogle Scholar
  3. 3.
    Kang MG, Choi HW, Lee JH et al (2016) Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget 7:57036–57049PubMedPubMedCentralGoogle Scholar
  4. 4.
    Rashid M, Ahmed Z, Ahmed S et al (2016) Coexisting JAK2V617F and CALR exon 9 mutation in essential thrombocythaemia. Indian J Hematol Blood Transfus 32:112–116CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cleyrat C, Chabot-Richards DS, Lynch DT et al (2017) Leukemic transformation of post-essential thrombocythemia myelofibrosis: a unique case presenting with double MPL and CALR mutations. Blood 130:4215Google Scholar
  6. 6.
    Jeromin S, Meggendorfer M, Fasan A et al (2017) Frequency of concurrent BCR-ABL1, JAK2, CALR and MPL mutations in a cohort of 5,545 cases with suspected MPN by a deep sequencing approach. EHA Learn Center 2017:181088Google Scholar
  7. 7.
    Usseglio F, Beaufils N, Calleja A et al (2017) Detection of CALR and MPL mutations in low allelic burden JAK2 V617F essential thrombocythaemia. J Mol Diagn 91:92–98CrossRefGoogle Scholar
  8. 8.
    Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S (2018) The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol 97:2071–2080CrossRefPubMedGoogle Scholar
  9. 9.
    De Roeck L, Michaux L, Debackere K et al (2018) Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. Hematology 23:785–792CrossRefPubMedGoogle Scholar
  10. 10.
    Mansier O, Paz DL, Lanotto JC et al (2018) Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am J Hematol 93:E84–E109CrossRefPubMedGoogle Scholar
  11. 11.
    Ramanan V, Kelkar K, Ranade S et al (2016) The clinical utility of a custom-developed targeted next-generation sequencing assay for detection of mutations associated with Philadelphia negative chronic myeloproliferative neoplasms: two case examples with CALR exon 9 mutations. Int J MolImmunoOncol 1:28–34Google Scholar
  12. 12.
    Bozeman, MT. Golden Helix GenomeBrowse® visualization tool (version 2.X) [software]. Golden Helix, Inc. Available from http://www.goldenhelix.com
  13. 13.
    Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8:15CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Pacilli A, Vannucchi AM, Passamonti F (2014) Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 89:E121–E124CrossRefPubMedGoogle Scholar
  15. 15.
    Pietra D, Rumi E, Ferretti VV, Buduo CAD, Milanesi C, Cavalloni C, Sant’Antonio E, Abbonante V, Moccia F, Casetti IC, Bellini M, Renna MC, Roncoroni E, Fugazza E, Astori C, Boveri E, Rosti V, Barosi G, Balduini A, Cazzola M (2016) Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 30:431–438CrossRefPubMedGoogle Scholar
  16. 16.
    Defour JP, Chachoua I, Pecquet C, Constantinescu SN (2016) Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms. Leukemia 30:1214–1216CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Anjali Diagnostic Pathology LaboratoryPuneIndia
  2. 2.MVR Welfare FoundationPuneIndia
  3. 3.GenePath Diagnostics India Pvt LtdPuneIndia
  4. 4.Yashoda Hematology ClinicPuneIndia
  5. 5.I-SHARE FoundationPuneIndia

Personalised recommendations